化学基因组学在抗真菌药物研究中的应用

摘要/Abstract

摘要： 真菌感染特别是侵袭性感染严重威胁人类健康,而我们应对真菌感染的药物种类却很少。基于细胞表型变化的抗真菌药物筛选,容易获得活性先导物,但后续对其作用靶点和作用机制的研究通常需要耗费更多的时间和精力,这已成为抗真菌药物研发的瓶颈。识别活性化合物的分子靶点,对于进一步优化改造先导物获得高效低毒的候选药物至关重要。化学基因组学能在活细胞基因组水平上发现先导物的作用靶点,利用该策略,近年来已有多个抗真菌先导物发现了作用靶点。该文主要介绍了化学基因组学的技术特点,以及近年来在发现抗真菌先导物作用靶点方面的应用。

中图分类号:

R978.5

高路, 吕权真, 甄诚, 阎澜, 姜远英. 化学基因组学在抗真菌药物研究中的应用[J]. 中国真菌学杂志, 2022, 17(3): 235-240.

参考文献

[1] LANIADO-LABORÍN R, CABRALES-VARGAS M N.Amphotericin B:side effects and toxicity[J]. Rev Iberoam Micol,2009,26(4):223-227.
[2] PAYNE D J, GWYNN M N, HOLMES D J, POMPLIANO D L.Drugs for bad bugs:confronting the challenges of antibacterial discovery[J]. Nat Rev Drug Discov,2007, 6(1):29-40.
[3] XUE A, ROBBINS N, COWEN L E. Advances in fungal chemical genomics for the discovery of new antifungal agents[J]. Ann N Y Acad Sci,2021, 1496(1):5-22.
[4] ZHOU F, LI S, ZHU Y.Integrating yeast chemical genomics and mammalian cell pathway analysis[J]. Acta Pharmacol Sin,2019, 40(9):1245-1255.
[5] 周富来.基于化学基因组学的活性化合物与新靶点发现[D].上海:中国科学院大学(中国科学院上海药物研究所),2019.
[6] LI Z, WANG H, CAI C.Genome-wide piggyBac transposon-based mutagenesis and quantitative insertion-site analysis in haploid Candida species[J]. Nat Protoc,2020, 15(8):2705-2727.
[7] MIELICH K, SHTIFMAN-SEGAL E, GOLZ J C.Maize transposable elements Ac/Ds as insertion mutagenesis tools in Candida albicans[J]. G3(Bethesda),2018, 8(4):1139-1145.
[8] SEGAL E S, GRITSENKO V, LEVITAN A.Gene essentiality analyzed by in vivo transposon mutagenesis and machine learning in a stable haploid isolate of Candida albicans[J]. Bio,2018, 9(5):e02048-18.
[9] DE CÁSSIA ORLANDI SARDI J, SILVA D R, SOARES MENDES-GIANNINI M J,et al.Candida auris:Epidemiology, risk factors, virulence, resistance, and therapeutic options[J]. Microb Pathog,2018, 125:116-121.DOI:10.1016/j.micpath.2018.09.014.
[10] ROEMER T, JIANG B, DAVISON J.Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery[J]. Mol Microbiol,2003, 50(1):167-181.
[11] WILSON R B, DAVIS D, MITCHELL A P.Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions[J]. Bacteriol,1999, 181(6):1868-1874.
[12] BAUDIN A, OZIER-KALOGEROPOULOS O, DENOUEL A.A simple and efficient method for direct gene deletion in Saccharomyces cerevisiae[J]. Nucleic Acids Res,1993, 21(14):3329-3330.
[13] GIAEVER G, SHOEMAKER D D, JONES T W.Genomic profiling of drug sensitivities via induced haploinsufficiency[J]. Nat Genet.1999, 21(3):278-283.
[14] SHOEMAKER D D, LASHKARI D A, MORRIS D.Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy[J]. Nat Genet, 1996, 14(4):450-456.
[15] GIAEVER G, FLAHERTY P, KUMM J.Chemogenomic profiling:identifying the functional interactions of small molecules in yeast[J]. Proc Natl Acad Sci U S A,2004, 101(3):793-798.
[16] LUM P Y, ARMOUR C D, STEPANIANTS S B.Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes[J]. Cell,2004, 116(1):121-137.
[17] DEUTSCHBAUER A M, JARAMILLO D F, PROCTOR M.Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast[J].Genetics,2005, 169(4):1915-1925.
[18] BUTCHER R A, BHULLAR B S, PERLSTEIN E O.Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway[J]. Nat Chem Biol, 2006, 2(2):103-109.
[19] KUZMIN E, COSTANZO M, ANDREWS B.Synthetic genetic arrays:automation of yeast genetics[J]. Cold Spring Harb Protoc,2016,(4):pdb.top086652.DOI:10.1101/pdb.top086652.
[20] TONG A H, EVANGELISTA M, PARSONS A B.Systematic genetic analysis with ordered arrays of yeast deletion mutants[J]. Science,2001, 294(5550):2364-2368.
[21] MANN P A, MCLELLAN C A, KOSEOGLU S.Chemical genomics-based antifungal drug discovery:targeting glycosylphosphatidylinositol (GPI) precursor biosynthesis[J]. ACS Infect Dis,2015, 1(1):59-72.
[22] XU D, JIANG B, KETELA T.Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans[J]. PLoS Pathog,2007, 3(6):e92.
[23] ROEMER T, XU D, SINGH S B.Confronting the challenges of natural product-based antifungal discovery[J]. Chem Biol,2011, 18(2):148-164.
[24] LAMB J, CRAWFORD E D, PECK D.The Connectivity map:using gene-expression signatures to connect small molecules, genes, and disease[J]. Science,2006, 313(5795):1929-1935.
[25] IORIO F, BOSOTTI R, SCACHERI E.Discovery of drug mode of action and drug repositioning from transcriptional responses[J]. Proc Natl Acad Sci U S A,2010, 107(33):14621-14626.
[26] LEE A Y, STONGE R P, PROCTOR M J.Mapping the cellular response to small molecules using chemogenomic fitness signatures[J]. Science.2014, 344(6180):208-211.
[27] HILLENMEYER M E, FUNG E, WILDENHAIN J.The chemical genomic portrait of yeast:uncovering a phenotype for all genes[J]. Science,2008, 320(5874):362-365.
[28] OLIVER J D, SIBLEY G E M, BECKMANN N.F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase[J]. Proc Natl Acad Sci U S A,2016, 113(45):12809-12814.
[29] CHAYAKULKEEREE M, JOHNSTON S A, OEI J B.SEC14 is a specific requirement for secretion of phospholipase B1 and pathogenicity of Cryptococcus neoformans[J]. Mol Microbiol,2011, 80(4):1088-1101.
[30] NILE A H, TRIPATHI A, YUAN P.PITPs as targets for selectively interfering with phosphoinositide signaling in cells[J]. Nat Chem Biol,2014, 10(1):76-84.
[31] FILIPUZZI I, COTESTA S, PERRUCCIO F.High-resolution genetics identifies the lipid transfer protein Sec14p as target for antifungal ergolines[J]. PLoS Genet,2016, 12(11):e1006374.
[32] HUANG Z, CHEN K, ZHANG J.A functional variomics tool for discovering drug-resistance genes and drug targets[J]. Cell Rep,2013, 3(2):577-585.